Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. They leverage world-class delivery systems and related technologies to bring new medicines to patients who need them. Genevant does this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows them to maintain our leadership position in the space. 

Biotechnology

Genevant Sciences

Pete Lutwyche

Gregg Ashby

James Heyes

Pete Zorn

Ed Yaworski

Tracy Meffen

The Scientific Development team at Genevant Sciences is responsible for advancing the company's nucleic acid drug development pipeline by leveraging cutting-edge lipid nanoparticle (LNP) technology and related delivery systems. This multidisciplinary team of scientists and engineers focuses on the innovation, optimization, and validation of new therapeutic candidates, collaborating closely with both internal and external partners to bring novel medicines from early discovery through to clinical development.

Scientific Development

Leadership Team

Scientific Development

About

Team members

Other teams at Genevant Sciences

Leadership Team